BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 31339892)

  • 1. Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.
    Fleischmann DF; Unterrainer M; Corradini S; Rottler M; Förster S; la Fougère C; Siepmann T; Schwaiger M; Bartenstein P; Belka C; Albert NL; Niyazi M
    PLoS One; 2019; 14(7):e0216111. PubMed ID: 31339892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilizing 18F-fluoroethyl-l-tyrosine positron emission tomography in high grade glioma for radiation treatment planning in patients with contraindications to MRI.
    Jaymanne DT; Kaushal S; Chan D; Schembri G; Brazier D; Bailey D; Wheeler H; Back M
    J Med Imaging Radiat Oncol; 2018 Feb; 62(1):122-127. PubMed ID: 28980392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy.
    Rieken S; Habermehl D; Giesel FL; Hoffmann C; Burger U; Rief H; Welzel T; Haberkorn U; Debus J; Combs SE
    Radiother Oncol; 2013 Dec; 109(3):487-92. PubMed ID: 23953407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FET-PET for malignant glioma treatment planning.
    Niyazi M; Geisler J; Siefert A; Schwarz SB; Ganswindt U; Garny S; Schnell O; Suchorska B; Kreth FW; Tonn JC; Bartenstein P; la Fougère C; Belka C
    Radiother Oncol; 2011 Apr; 99(1):44-8. PubMed ID: 21458093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Margin reduction in radiotherapy for glioblastoma through
    Fleischmann DF; Unterrainer M; Schön R; Corradini S; Maihöfer C; Bartenstein P; Belka C; Albert NL; Niyazi M
    Radiother Oncol; 2020 Apr; 145():49-55. PubMed ID: 31923709
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Fleischmann DF; Unterrainer M; Bartenstein P; Belka C; Albert NL; Niyazi M
    J Neurooncol; 2017 Apr; 132(2):277-286. PubMed ID: 28102485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients.
    Niyazi M; Jansen NL; Rottler M; Ganswindt U; Belka C
    Radiat Oncol; 2014 Dec; 9():299. PubMed ID: 25529015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
    Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of
    Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
    Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume.
    Piroth MD; Galldiks N; Pinkawa M; Holy R; Stoffels G; Ermert J; Mottaghy FM; Shah NJ; Langen KJ; Eble MJ
    Radiat Oncol; 2016 Jun; 11():87. PubMed ID: 27342976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of
    Moller S; Law I; Munck Af Rosenschold P; Costa J; Poulsen HS; Engelholm SA; Engelholm S
    Radiother Oncol; 2016 Oct; 121(1):132-137. PubMed ID: 27622554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of
    Debus C; Waltenberger M; Floca R; Afshar-Oromieh A; Bougatf N; Adeberg S; Heiland S; Bendszus M; Wick W; Rieken S; Haberkorn U; Debus J; Knoll M; Abdollahi A
    Sci Rep; 2018 May; 8(1):7201. PubMed ID: 29740097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for differentiation of glioma recurrence from radionecrosis using integrated
    Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
    Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma.
    Popp I; Bott S; Mix M; Oehlke O; Schimek-Jasch T; Nieder C; Nestle U; Bock M; Yuh WTC; Meyer PT; Weber WA; Urbach H; Mader I; Grosu AL
    Radiother Oncol; 2019 Jan; 130():121-131. PubMed ID: 30219612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma.
    Weber DC; Zilli T; Buchegger F; Casanova N; Haller G; Rouzaud M; Nouet P; Dipasquale G; Ratib O; Zaidi H; Vees H; Miralbell R
    Radiat Oncol; 2008 Dec; 3():44. PubMed ID: 19108742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy.
    Hirata T; Kinoshita M; Tamari K; Seo Y; Suzuki O; Wakai N; Achiha T; Umehara T; Arita H; Kagawa N; Kanemura Y; Shimosegawa E; Hashimoto N; Hatazawa J; Kishima H; Teshima T; Ogawa K
    J Neurosurg; 2019 Sep; 131(3):676-686. PubMed ID: 30239314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological tumour volumes of gliomas in early and standard 20-40 min
    Unterrainer M; Winkelmann I; Suchorska B; Giese A; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1242-1249. PubMed ID: 29487977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients.
    Vees H; Senthamizhchelvan S; Miralbell R; Weber DC; Ratib O; Zaidi H
    Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):182-93. PubMed ID: 18818918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.